Azelastine Allergen Chamber - Onset of Action Study

Clinical Trial Summary

This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day treatment at home.

See also
Status	Clinical Trial	Phase
Terminated	`NCT01337323` - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting	N/A
Completed	`NCT01171664` - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects	Phase 2
Completed	`NCT00784732` - A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber	Phase 2
Completed	`NCT00578929` - Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients	Phase 3
Completed	`NCT00619827` - Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract	Phase 1
Completed	`NCT00209365` - The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit	N/A
Terminated	`NCT00223587` - Seasonal Allergic Rhinitis and Driving Ability	Phase 4
Completed	`NCT00637455` - Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel	Phase 4
Completed	`NCT00963599` - Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)	Phase 3
Recruiting	`NCT05346718` - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis	N/A
Completed	`NCT02245360` - Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis	Phase 3
Completed	`NCT01940146` - Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis	Phase 2
Completed	`NCT01230619` - Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis	Phase 2
Completed	`NCT00561717` - A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis	Phase 4
Completed	`NCT00574210` - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)	Phase 2
Completed	`NCT00420082` - A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber	Phase 2
Completed	`NCT00405899` - Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections	N/A
Completed	`NCT00443495` - Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis	Phase 1/Phase 2
Completed	`NCT03097432` - Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment	N/A
Completed	`NCT05540717` - Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen	Phase 3

NCT number	NCT06126952
Study type	Interventional
Source	Viatris Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	October 30, 2023
Completion date	March 18, 2024

Azelastine Allergen Chamber - Onset of Action Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms